User menu

Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.

Bibliographic reference Flourié, B ; Hagège, H ; Tucat, G ; Maetz, D ; Hébuterne, X ; et. al. Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.. In: Alimentary Pharmacology and Therapeutics, Vol. 37, no.8, p. 767-775 (2013)
Permanent URL
  1. Hanauer Stephen B, Medical therapy for ulcerative colitis 2004, 10.1053/j.gastro.2004.02.071
  2. Travis S.P.L., Stange E.F., Lémann M., Øresland T., Bemelman W.A., Chowers Y., Colombel J.F., D'Haens G., Ghosh S., Marteau P., Kruis W., Mortensen N.J.McC., Penninckx F., Gassull M., European evidence-based Consensus on the management of ulcerative colitis: Current management, 10.1016/j.crohns.2007.11.002
  3. Hussain F. N., Ajjan R. A., Kapur K., Moustafa M., Riley S. A., Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters, 10.1046/j.1365-2036.2001.00891.x
  4. Gandia Peggy, Idier Isabelle, Houin Georges, Is Once-Daily Mesalazine Equivalent to the Currently Used Twice-Daily Regimen? A Study Performed in 30 Healthy Volunteers, 10.1177/0091270006296522
  5. Kane Sunanda V., Cohen Russell D., Aikens James E., Hanauer Stephen B., Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis, 10.1111/j.1572-0241.2001.04683.x
  6. Shale M. J., Riley S. A., Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease, 10.1046/j.1365-2036.2003.01648.x
  7. KANE S. V., Systematic review: adherence issues in the treatment of ulcerative colitis, 10.1111/j.1365-2036.2006.02809.x
  8. Kamm Michael A., Sandborn William J., Gassull Miguel, Schreiber Stefan, Jackowski Lechoslaw, Butler Todd, Lyne Andrew, Stephenson David, Palmen Mary, Joseph Raymond E., Once-Daily, High-Concentration MMX Mesalamine in Active Ulcerative Colitis, 10.1053/j.gastro.2006.10.011
  9. Lichtenstein Gary R., Kamm Michael A., Boddu Prabhakar, Gubergrits Natalya, Lyne Andrew, Butler Todd, Lees Kirstin, Joseph Raymond E., Sandborn William J., Effect of Once- or Twice-Daily MMX Mesalamine (SPD476) for the Induction of Remission of Mild to Moderately Active Ulcerative Colitis, 10.1016/j.cgh.2006.10.025
  10. Kruis W, Kiudelis G, Racz I, Gorelov I A, Pokrotnieks J, Horynski M, Batovsky M, Kykal J, Boehm S, Greinwald R, Mueller R, , Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial, 10.1136/gut.2008.154302
  11. Hanauer, Am J Gastroenterol, 88, 1188 (1993)
  12. Marteau P, Combined oral and enema treatment with Pentasa (mesalazine) is superior to oral therapy alone in patients with extensive mild/moderate active ulcerative colitis: a randomised, double blind, placebo controlled study, 10.1136/gut.2004.060103
  13. Sutherland Lloyd R., Martin Francois, Greer Scott, Robinson Malcolm, Greenberger Norton, Saibil Fred, Martin Thomas, Sparr Joseph, Prokipchuk Ed, Borgen Lowell, 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis, 10.1016/0016-5085(87)90621-4
  14. Rachmilewitz D., Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial., 10.1136/bmj.298.6666.82
  15. Pineton de Chambrun Guillaume, Peyrin-Biroulet Laurent, Lémann Marc, Colombel Jean-Frédéric, Clinical implications of mucosal healing for the management of IBD, 10.1038/nrgastro.2009.203
  16. Colombel Jean Frédéric, Rutgeerts Paul, Reinisch Walter, Esser Dirk, Wang Yanxin, Lang Yinghua, Marano Colleen W., Strauss Richard, Oddens Björn J., Feagan Brian G., Hanauer Stephen B., Lichtenstein Gary R., Present Daniel, Sands Bruce E., Sandborn William J., Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis, 10.1053/j.gastro.2011.06.054
  17. Dave, Gastroenterol Hepatol, 8, 29 (2012)
  18. Bokemeyer Bernd, Hommes Daan, Gill Ivo, Broberg Per, Dignass Axel, Mesalazine in left-sided ulcerative colitis: Efficacy analyses from the PODIUM trial on maintenance of remission and mucosal healing, 10.1016/j.crohns.2011.10.006
  19. SANDBORN W. J., KAMM M. A., LICHTENSTEIN G. R., LYNE A., BUTLER T., JOSEPH R. E., MMX Multi Matrix System®mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials, 10.1111/j.1365-2036.2007.03361.x
  20. NAVARRO F, Treatment of inflammatory bowel disease: safety and tolerability issues, 10.1016/j.amjgastroenterol.2003.11.001
  21. Schreiber S, Hamling J, Zehnter E, Howaldt S, Daerr W, Raedler A, Kruis W, Renal tubular dysfunction in patients with inflammatory bowel disease treated with aminosalicylate., 10.1136/gut.40.6.761
  22. Van Staa Tjeerd P., Travis Simon, Leufkens Hubert G.M., Logan Richard F., 5-aminosalicylic acids and the risk of renal disease: A large British epidemiologic study☆, 10.1053/j.gastro.2004.03.016